innovate.collaborate.change

the cancer collaborative
3
come on in

bridging science, policy and advocacy

how we’re different  the cancer collaborative is a hub for the cancer community. created to foster an environment of collaboration amongst science, policy and advocacy in order to make a meaningful contribution to cancer care.  our goal is to co-create and collaborate with stakeholders to proactively identify the challenges and opportunities, prioritize them and work together to make action-oriented changes on how cancer care is delivered in canada and beyond. better outcomes for cancer patients in canada can only be achieved when we let go of old ideologies- embracing innovation, encouraging collaboration, creating collective purpose and fundamentally changing. bold ideas and fuelling dialogues that adapt and adopt to shifting paradigms.
about colab
we can be the catalyst for change
FIND OUT MORE
EXPLORE THE CANCER COLLABORATIVE
our PROJECTS
car-t cell therapy
accelerating adoption through collaboration
car-t cell therapy has entered clinical practice.  such a paradigm-shifting and novel cancer therapy that relies on viral production, genetic- modification, cell expansion, quality control/quality analysis, as well as clinical application and toxicity management poses significant challenges to regulatory and reimbursement approval.  .
MORE
biosimilars
expanding access to create sustainability
biosimilar medicines represent a rapidly emerging field that can offer improved accessibility to medicines for patients at reduced expenditure for healthcare systems that are tackling issues of sustainability. the next two years will be important for biosimilars uptake and impact.  biosimilars uptake in oncology can positively impact the financial burden of healthcare systems with the cost savings being reallocated to improve overall health system outcomes, globally.
MORE
personalised medicine
cracking the cancer code
personalized medicine and biomarkers present an incredible opportunity to revolutionize health care. it has the potential to change the way we think about, identify and manage cancer care. the impact on both clinical research and patient care will grow as our understanding and technologies improve transforming the delivery of cancer care to benefit both patients and cancer care systems.
MORE
immuno-oncology
tipping pIOnt
immuno-oncology [IO] therapies continue to create breakthroughs however real world challenges and significant shifts in value across healthcare systems create barriers to access for patients.
MORE

managing innovation in oncology

catalysts for change in cancer care
the next decade in healthcare will look nothing like the last- oncology is experiencing a tidal wave of therapies and technologies that continues to profoundly change the way cancer is diagnosed, treated, and monitored. the arrival of novel and disruptive technologies, precision medicine and emerging technologies, will drive oncology onward and the decisions taken today will have an impact on the landscape over the next decade.  industry, regulators, HTA, pricing agencies, health care professionals, researchers and patient advocates must work together to address these challenges and create solutions to overcome these clinical, regulatory, reimbursement and policy hurdles.
MORE

capacity building

building better advocates
the cancer collaborative considers advocacy an important tool in improving cancer care at provincial, national and global levels and patient advocates who are well informed and who have a thorough understanding of the clinical and political landscape can better identify, shape and influence policy and develop effective advocacy strategies and communication with decision makers. strengthening their capacity to address québec specific challenges and opportunities, and to better understand, respond and engage within the pan-canadian environment to proactively engage in an effective and efficient manner.
MORE
EXPLORE THE EVENTS
our WEBINARs
watch the recording here
LATEST POST
our BLOG

why precision medicine matters

Nov 17, 2021 | ,

when we talk about mutations, this represents a very small amount of cancer patients - in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively].  however, this actually represents respectively-...

why precision medicine matters

Nov 17, 2021 | ,

when we talk about mutations, this represents a very small amount of cancer patients - in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively].  however, this actually represents respectively-...

let’s talk about biomarkers – BRAF

Nov 10, 2021 | ,

BRAF represents one of the most frequently mutated protein kinase genes in human tumours. BRAF mutation is seen in melanoma, papillary thyroid carcinoma [including papillary thyroid carcinoma arising from ovarian teratoma], ovarian serous tumours, colorectal...

LATEST PUBLICATION
our REPORTS
Get our latest colab notebooks and briefs –>  MORE

cancercolab

we can be the catalyst for change.
fostering an environment of co-creation & collaboration to make action-oriented changes in cancer care in canada.

CONTACT US

hello@cancercolab.ca

#cancercolab
#travelwithcolab

the cancer collaborativeFollow

the cancer collaborative
cancercolabthe cancer collaborative@cancercolab·
31 Dec

we’re excited for the changes coming to the cancer collaborative in 2022 and the strategic priorities we have planned. we can’t wait to share - until then wishing you all a wonderful start to 2022

Reply on Twitter 1476931389958283275Retweet on Twitter 1476931389958283275Like on Twitter 14769313899582832751Twitter 1476931389958283275
cancercolabthe cancer collaborative@cancercolab·
30 Nov

fittingly on this last day of november and #precisionmedicine awareness month we’re tuned in to @GenomeCanada town hall on the future of genomics in canada

Reply on Twitter 1465731104271446023Retweet on Twitter 14657311042714460231Like on Twitter 1465731104271446023Twitter 1465731104271446023
Load More...